2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Treatment Considerations, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Pharmacology, Biological Processes, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

2380 GMP-compatible manufacturing generates regulatory CD8 trp cells with preserved immunoregulatory function

Qi Zhang, Yipeng Xu2, Bixia Wang Jr3, Huidong Guo4, Xiaojun Huang, MD,PhD5
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, China
5 Frontiers Science Center for Cancer Integrative Omics, Beijing, China, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
Adoptive regulatory T-cell therapy offers a promising strategy for restoring immune tolerance after allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet its clinical translation remains limited by the scarcity, phenotypic instability, and manufacturing complexity of regulatory T-cell populations. Here, we developed a rapid, GMP-compatible 12-day manufacturing platform for generating human CD8 regulatory precursor T-cell (CD8 Trp; CD8?CD27?HLA-DR?) products from bulk peripheral blood CD8? T cells. Expansion of bulk CD8? T cells followed by post-expansion CD27?HLA-DR? enrichment increased the projected manufacturing yield by approximately 45-fold relative to direct expansion of preselected CD8 Trp cells while enhancing FOXP3 expression. Single-cell transcriptomic and paired T-cell receptor analyses demonstrated that expanded CD8 Trp cells retained the core molecular identity of CD8 Trp cells, displayed enhanced regulatory transcriptional programs, and exhibited substantially greater clonal diversity than cells generated by direct expansion of preselected CD8 Trp cells, indicating that regulatory CD8 T-cell programs can be established during ex vivo expansion. Functionally, expanded CD8 Trp cells potently suppressed human T-cell activation and proliferation in vitro and significantly attenuated xenogeneic graft-versus-host disease in vivo. Sustained CD27 expression throughout culture enabled HLA-DR-based enrichment alone, providing a scalable magnetic bead-based alternative to dual-marker cell sorting. The HLA-DR? fraction was enriched for FOXP3, CTLA4, and Helios, and magnetically enriched HLA-DR? cells demonstrated in vivo efficacy comparable to that of CD27?HLA-DR? cells isolated by fluorescence-activated cell sorting. In contrast, CD8+ T cells from patients with systemic lupus erythematosus failed to acquire a regulatory phenotype comparable to that of healthy donor-derived cells during expansion, supporting healthy donor CD8? T cells as the preferred manufacturing source. Collectively, these findings establish a scalable manufacturing platform for expanded CD8 Trp cell products and provide new insight into the plasticity of regulatory CD8 T-cell differentiation, thereby laying the foundation for next-generation tolerance-inducing cellular therapies for transplantation and other immune-mediated diseases.
Qi Zhang: No relevant conflicts of interest to declare.